Pliant Therapeutics Inc
(STU:9PT)
€
12.5
-0.7 (-5.3%)
Market Cap: 778.32 Mil
Enterprise Value: 448.21 Mil
PE Ratio: 0
PB Ratio: 2.37
GF Score: 36/100 Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023 / 06:40PM GMT
Release Date Price:
€26.2
Jeff Jones
Oppenheimer & Co. Inc. - Analyst
Good afternoon, everyone, and welcome to the Pliant Therapeutics fireside chat here at the Oppenheimer healthcare conference. I'm Jeff Jones. I'm a senior analyst here on the biotechnology team, and I'm thrilled to welcome the CEO, Bernard Coulie; and the Chief Medical Officer, Ãric Lefebvre.
Welcome, gentlemen. Thank you very much for taking the time to join us this afternoon.
Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO
Thanks, Jeff.
Questions & Answers
Jeff Jones
Oppenheimer & Co. Inc. - Analyst
I guess, to start off, I start off with, for those who aren't familiar with the story, can you give us a quick overview of the company and in particular, your integrin-targeting technology platform?
Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO
Absolutely. So at Pliant, we have been really focused for the past, I would say, six years on developing novel treatments for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot